CHATHAM – Chatham Borough Mayor Richard Plambeck said this week that he has been diagnosed with a chronic form of leukemia called chronic myelogenous leukemia or CML. The mayor said he is undergoing chemotherapy.
Plambeck, who was sworn in this year to a four-year term as mayor, said he was diagnosed two weeks ago. He said the diagnosis would not present a conflict with his mayoral duties.
“I’m feeling fine,” the mayor said this week.
Plambeck said he first became aware that something was wrong when he lost five pounds. But he voiced confidence in his doctors and the treatment he is now undergoing.
Mostly, he said, “I have a good supporting family.”
According to the U.S. National Library of Medicine, CML is “a malignant cancer of the bone marrow that causes rapid growth of the blood forming cells (known as myeloid precursors) in the bone marrow, peripheral blood, and body tissues.”
CML, according to the Library of Medicine, accounts for 7-20 percent cases of leukemia.
“The vast majority of people treated for cancer with radiation do not go on to develop leukemia and it takes many years to develop leukemia from this cause,” according to the Library of Medicine.
“If people notice me drinking a lot of water, this is the reason,” said the mayor.
Thursday, August 19, 2004
Detection of BCR/ABL Fusion Product in Normoblasts in a Case of Chronic Myelogenous Leukemia.
Erythroblast phase of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute erythroid leukemia are rare events. The distinction between these two entities is poorly defined. The World Health Organization (WHO) classification requires the presence of more than 50% of erythroblasts in the bone marrow for the diagnosis of both the erythroid/myeloid or pure erythroid subtypes of acute erythroid leukemia. However, in previous studies of erythroblast crisis CML, the percentage of erythroid series in the bone marrow is seldom mentioned and the direct relationship of the erythroblasts and the Philadelphia chromosome has never been established. We report a well-documented case of acute erythroid leukemia transformed from CML. The studies in morphology, immunohistochemistry, and flow cytometry fulfill the WHO criteria for the diagnosis of acute erythroid leukemia, and yet the complex karyotype containing Philadelphia chromosome indicates genetic evolution. Finally, the direct demonstration of the BCR/ABL fusion product by fluorescence in situ hybridization in the erythroblasts provides concrete evidence that the erythroblasts are part of the leukemic process and not an innocent bystander.
Preliminary research suggests that benzene emissions from gas stations and auto repair shops may quadruple the risk of leukemia in children.
Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias.
, Yoshida H
, Pan L
, Min Luo J
, Fujisawa S
, Naito K
, Nakamura S
, Shinjo K
, Takeshita A
, Ohno R
, Ohnishi K
CREB-binding protein (CBP) and highly related p300 protein are transcriptional co-activators that play an essential role in chromatin remodeling through histone acetyltransferase activity and interaction with other transcriptional regulators. In this study, various hematological malignancies, including nine cell lines and 45 clinical samples (32 acute myeloid leukemias (AML), nine acute lymphoblastic leukemias (ALL), two cases of myelodysplastic syndrome (MDS), one multiple myeloma, and one chronic myelogenous leukemia in blast crisis), were examined to ask whether mutation of the CBP and p300 genes could be involved in leukemogenesis. The answer was approached by employing the reverse transcription-polymerase chain reaction and single-strand conformation polymorphism (RT-PCR/SSCP) technique and subsequent sequence analysis. A T-lymphoblastic cell line, CEM had an in-frame 21-base-pair deletion within the bromodomain of its p300 cDNA. Genomic DNA analysis revealed aberrant splicing caused by mutation of the acceptor site of intron 17 from ag to gg, which should interfere with catalytic step II of the pre-mRNA splicing reaction. In 1 MDS patient, a missense mutation was detected, which caused a replacement from Ser to Gly at codon 507 of p300. This is the first report of CBP/p300 mutations in leukemias, which might be relatively rare but nonetheless contribute to pathogenesis in some fraction of cases.
Cytogenetic and hematological spontaneous remission in a case of acute myelogenous leukemia.
Several cases of spontaneous remission (SR) interrupting the invariably progressive course of untreated acute myeloblastic leukemia (AML) have been reported so far. We shall add to this series the hematological and cytogenetic SR occurring in a 72-yr-old man affected by AML following myelodysplastic syndrome. At diagnosis cytogenetic analysis showed the 48, xy, del (6) (p22-pter), +13, +14 karyotype. Owing to a lobar pneumonia, the chemotherapy was deferred and a broad spectrum antibiotic therapy was established. Supportive care included red cells and platelet transfusions and low-dose corticosteroid. Two months later, after the pneumonia had completely disappeared, a complete remission, lasting about 5 months, was documented on bone marrow morphological and cytogenetical examination, although some degree of myeloid dysplasia persisted. Possible mechanisms of the various SRs described during the course of AML are discussed with a review of the literature.
Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.
In order to investigate the mechanism of interferon-alpha (IFNalpha) action in the treatment of chronic myelogenous leukemia (CML), we examined surface expressions of both type I interferon receptor 1 (IFNAR1) and 2 (IFNAR2) subunits on CD34-positive cells in bone marrow (BM) in a total of 57 CML patients. Initial cell-surface IFNAR2 expression at diagnosis assessed by flow cytometry widely distributed but showed overall significantly higher expression in CML patients when compared with normal controls. In 15 fresh patients who subsequently received IFNalpha therapy, IFNAR2 expression at diagnosis was significantly higher in cytogenetic good responders than in poor responders. Down-regulation of IFNAR2 expression during IFNalpha therapy was observed only in good responders but not in poor responders. In addition to protein level, both initial high IFNAR2c mRNA expression level and its down-regulation during IFNalpha therapy, in purified CD34-positive cells, were also observed only in good responders. In contrast to IFNAR2, cell-surface IFNAR1 expression was generally lower than IFNAR2, and correlation between either the pretreatment level or down-regulation of IFNAR1 and clinical response was not evident. With in vitro IFNalpha stimulation, CD34-positive cells showed down-regulations of cell-surface IFNAR2, and IFNAR1 to a lesser extent, in one good-responder patient, but not in one poor-responder patient. Serum soluble interferon receptor (sIFNR) was higher in untreated CML patients than in normal controls, without any correlation with clinical response to IFNalpha. Thus, the pretreatment protein and mRNA expression levels of IFNAR2 and their down-regulations during IFNalpha therapy correlate well with IFNalpha response in CML patients.
The name CMLHOPE.COM has been chosen for the new unified CML site that will soon be lauched. The new site will serve as a central portal for the various services and resources that are provided worldwide for CML patients through the network of the CML Support Group. The name reflects the many advances in treatment methods that have been made since the CML Support Group was started in 1997 and the promising research and new treatment methods that are anticipated in the future.
CMLHOPE.COM will be the home of both existing and new resources for Chronic Myelogenous Leukemia (aka Chronic Myeloid Leukemia) (CML) patients, caregivers, and professionals.
CML Support Group
The largest support group in the world for CML patients. Founded in 1997.
CML Support News
Daily newsfeed of the latest medical articles and news on CML.
An international network of local support groups for CML patients which covers over 60 countries. New features of Meetup will allow those interested to apply to become local CML organizers in their own community to schedule local support group and social events.
The new site will feature a new state of the art web message board system which can be used by registered members of CMLHOPE.COM
Links to selected and trusted sources of information for CML patients, caregivers, and professionals
CML Clinical Trials
An easy to use search function will locate the most current CML Clinical Trials.
In addition to Zavie’s regular chats on Yahoo, new chat technology is also being considered for inclusion in the new site to allow more to participate in regular chats.
The new CML Store will provide a selection of CMLHOPE.COM and CML Meetup merchandise including shirts, cups, and other logo merchandise which will be available for purchase. There will also be a book section that will allow CML patients to purchase books that other CML patients have found useful.
The new site will include an automated section for letter writing that will allow CML patients, caregivers, and others to write letters to their local newspapers and to state and federal elected officials on issues that are of concern to the CML community. Messages will be sent electronically and will be at no cost to users.
The new site will include backup archives of new messages starting in 2004 with improved search access.
Additional features and resources will be announced after the site has launched.
c 2004 CMLHOPE.COM
An athlete in a Single Sculls practices at the Schinias Rowing and Canoeing Center, outside Athens.